Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06332391 · ClinicalTrials.gov registry record · NA

Paced Heart Rate Acceleration for Cardiac Conditioning

A NA study of Heart Failure, Systolic, sponsored by Denice Hodgson-Zingman, MD.

Recruiting
Registry status
NA
Development phase
52
Enrollment target
1
Study location

NCT06332391: Recruiting NA study of Heart Failure, Systolic, sponsored by Denice Hodgson-Zingman, MD.

NCT06332391 is a NA study of Heart Failure, Systolic that is actively recruiting participants, run by Denice Hodgson-Zingman, MD. The registered enrollment target is 52 participants, below the 332-participant average among 13 other Heart Failure, Systolic trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06332391, a NA study of Heart Failure, Systolic, is actively recruiting participants, sponsored by Denice Hodgson-Zingman, MD.

RECRUITING
Registry status
NA
Development phase
52 participants
Enrollment target
1
Study location

Study Summary

A clinical trial of exercise-similar heart rate acceleration delivered via cardiac pacing vs. sham intervention in subjects at rest will be performed. The study population comprises subjects with guideline-directed medically managed left ventricular dysfunction due to ischemic or non-ischemic cardiomyopathy and an existing implantable cardioverter defibrillator or biventricular implantable cardioverter defibrillator. The purpose of the study is to understand how the heart rate pattern of exercise contributes to the considerable cardiac conditioning effects of exercise and estimate whether the pacing approach may have translational clinical applicability. Fifty-two subjects will be randomized, single-blinded, to either the pacing intervention or a sham intervention which they will receive once daily, 3 days/week for 6 weeks. Baseline symptoms and clinical test results will be compared to the same measures at 2 weeks, 4 weeks and 6 weeks of intervention/sham and at 3 months and one-year post-intervention. The primary endpoint will be the change in left ventricular ejection fraction from baseline in intervention vs. sham groups (mixed effects linear regression with time and treatment arm as fixed effects and pre-specified covariates of sex and cardiomyopathy type as random effects). Secondary endpoints will include changes in quality of life, 6-minute walk distance, cardiopulmonary exercise test (CPET) measures, daily activity and major adverse cardiac events (MACE) at 3 and 12 months between pacing and sham groups. A "dose-response" analysis of outcomes at 2, 4, and 6 weeks of the intervention vs. sham compared with baseline will be performed.

Primary Outcome

The change in left ventricular ejection fraction from baseline as determined by echocardiography

Conditions Studied

Interventions

  • DEVICE Exercise-similar cardiac pacing
  • DEVICE Sham cardiac pacing

Study Locations (1)

Iowa

  • University of Iowa Hospitals and Clinics - Iowa City

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2024-06-26
Est. Completion 2028-11-30
Phase NA
Denice Hodgson-Zingman, MD

1 total trials

What NCT06332391 shows while recruiting

NCT06332391 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 332-participant average among 13 other Heart Failure, Systolic trials with a reported enrollment target (84% lower).

The record links to 1 condition, with Heart Failure, Systolic appearing as the primary indexed condition, and to 2 interventions - of which Exercise-similar cardiac pacing is the first listed.

NCT06332391 reports a single indexed study location in Iowa.

Frequently Asked Questions

What is clinical trial NCT06332391 about?

NCT06332391 is a clinical study titled "Paced Heart Rate Acceleration for Cardiac Conditioning". A clinical trial of exercise-similar heart rate acceleration delivered via cardiac pacing vs. sham intervention in subjects at rest will be performed. The study population comprises subjects with guideline-directed medically managed left ventricular dysfunction due to ischemic or non-ischemic cardio...

What is the current status of trial NCT06332391?

This trial is currently recruiting. It is a NA study. The enrollment target is 52 participants. The study started on 2024-06-26. Estimated completion is 2028-11-30.

What conditions does trial NCT06332391 study?

This clinical trial studies the following conditions: Heart Failure, Systolic.

What interventions are being tested in trial NCT06332391?

The interventions under investigation include: Exercise-similar cardiac pacing (DEVICE), Sham cardiac pacing (DEVICE).

Who is sponsoring clinical trial NCT06332391?

This trial is sponsored by Denice Hodgson-Zingman, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06332391 being conducted?

This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure, Systolic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06332391's enrollment target sits among peer trials

52 8th of 13 higher than 6 of 13 other Heart Failure, Systolic trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure, Systolic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02630121 · 52 participants · Phase 4

    Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

  • NCT03629171 · 52 participants · Phase 2

    Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

  • NCT04128748 · 52 participants · Phase 1

    Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

  • NCT04150497 · 52 participants · Phase 1

    Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06332391, the US trial registry maintained by the National Library of Medicine. NCT06332391 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.